

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, GREAT BRITAIN, JAPAN, NEW ZEALAND, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THE PRESS RELEASE.

AroCell publishes prospectus in connection with forthcoming rights issue

The Board of Directors of AroCell AB (publ) ("AroCell" or the "Company") has, in connection with the forthcoming rights issue of approximately SEKm 86 (the "Rights Issue"), which was proposed and announced on 17 December 2021, and approved by the Extraordinary General Meeting on 19 January 2022, prepared a Swedish language EU Growth prospectus (the "Prospectus"). The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority.

Summary

- Each existing share in the Company held on the record date 26 January 2022 entitles to one (1) subscription right. One (1) subscription right entitles to subscription of one (1) new share, i.e., a subscription ratio of 1:1.
- The subscription price is SEK 0.75 per new share, which, assuming the Rights Issue is fully subscribed, results in the Company receiving issue proceeds of approximately SEKm 86 before deduction of transaction costs.
- The subscription rights are traded on Nasdaq First North Growth Market from and including January 31 2022 up to and including through February 9 2022.
- The subscription period runs from and including 31 January 2022 up to and including 14 February 2022.
- The Company has received subscription commitments and has entered into agreements on guarantee commitments of approximately SEKm 86, which secures the Rights issue up to 100 percent.

For complete information on the terms and conditions of the Rights Issue, please see the published Prospectus.

Prospectus

The Prospectus has been prepared in connection with the forthcoming Rights Issue and has today, on 26 January 2022, been approved and registered by the Swedish Financial Supervisory Authority. The Prospectus, containing complete terms and conditions, is available on the Company's, Nordic Issuing's and Redeye AB's respective websites (www.arocell.com, www.nordic-issuing.se, www.redeye.se). The Prospectus will also be available on the Swedish Financial Supervisory Authority's website (www.fi.se). Subscription forms will be available on the Company's, Nordic Issuing's, and Redeye AB's respective websites.

Timetable for the Rights Issue

26 January 2022	Record date
31 January – 9 February 2022	Trading in subscription rights
31 January – 14 February 2022	Subscription period
31 January 2022 – Until the Rights Issue is registered at the Swedish Companies Registration Office	Trading in paid subscription shares (Sw. "BTA")
Around 17 February 2022	Estimated publication of outcome in the Rights Issue

Advisers

Redeye AB acts as financial adviser and Wigge & Partners Advokat KB acts as legal adviser in connection with the Rights Issue. Nordic Issuing AB acts as issuing agent in connection with the Rights Issue.

For further information, please contact:

Anders Hultman, CEO

Phone: +46 (0)18 50 30 20

Email: anders.hultman@arocell.com

This information was submitted for publication, through the agency of the contact person set out above, at 17:35 CET on 27 January 2022.

IMPORTANT INFORMATION

The information in this press release does not constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in AroCell. No action has been taken and measures will not be taken to allow an offer to the public in any jurisdiction other than Sweden. The invitation to interested persons to subscribe for shares in AroCell will only be made through the Prospectus, which was published by the Company on 26 January 2022.

Neither subscription rights, paid subscribed shares ("**BTA**") nor newly issued shares have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTAs or newly issued shares have been registered or will be registered under the United States Securities Act of 1933 in its current wording, or under any other applicable law in the United States, Australia, Great Britain, Hong Kong, Japan, Canada, New Zealand, South Africa or in any other country where the Rights Issue or Private Placement or distribution of the press release is contrary to applicable laws or regulations or requires that further prospectuses be prepared, registered or that any other measure is taken in addition to what is required by Swedish law. Accordingly, the press release, as well as the prospectus, application form and other documents attributable to the Rights Issue and Private Placement, may not be distributed to or within any such jurisdiction.

This announcement may include forward-looking statements, which are based on AroCell's current expectations and projections about future events and financial and operational development. Words such as "intends", "will", "expects", "anticipates", "may", "plans", "estimates", and other expressions that imply indications or predictions of future developments or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future performance or development and actual results may differ materially from what is expressed in forward-looking information.

This information, the opinions, and forward-looking statements contained in this announcement are applied only at this date and are subject to change without notice. AroCell makes no commitments to disclose updates or revisions to forward-looking information, future events, or similar circumstances, other than as required by applicable law

This English announcement is an unofficial translation of the original Swedish announcement. In case of any discrepancies between the Swedish announcement and the English translation, the Swedish announcement shall prevail.

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare and established in various markets. In oncology, AroCell uses various biomarkers, TK1 and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com

Attachments

[AroCell publishes prospectus in connection with forthcoming rights issue](#)